Biocardia stock.

The estimated Net Worth of Peter Altman is at least $747 Mille dollars as of 28 June 2019. Peter Altman owns over 600 units of BioCardia stock worth over $69,056 and over the last 6 years he sold BCDA stock worth over $0. In addition, he makes $677,501 as President, Chief Executive Officer e Director at BioCardia.

Biocardia stock. Things To Know About Biocardia stock.

Reported on 11/7/23. Get the latest BioCardia Inc (BCDA) real-time quote, historical performance, charts, and other financial information to help you make more informed …The treated group median 6MWT at 12M increased 36.1 with a standard deviation of ±70.8 meters, and the control group median 6MWT increased at 12M by 33.4 meters ± 74.8 meters (p =0.6). Results ...Stock screener. Filter, compare, and track stocks. Insiders trading. See how executives trade. Heat map. Visualize ratios & metrics. Histogram. See ratios across industries. ... As the Vice President - Operations of BioCardia, the total compensation of Phil Pesta at BioCardia is $276,000.As of November 6, BioCardia’s shares were trading at $0.405. Over the past 52 weeks, the stock has experienced a significant decline of 78.11%. While BioCardia has achieved an average annual earnings growth rate of 3.7%, the Biotechs industry has seen earnings grow at a much higher rate of 21.9% annually. To stay updated on all of BioCardia ...

Real stock prices are not the same as the last traded stock price. Real stock prices are adjustments to closing stock prices. The adjustments are used in a variety of ways, including dividends, the range of prices and the closing price of t...

Nov 29, 2023 · On Tuesday, BioCardia Inc. [NASDAQ:BCDA] saw its stock fall -0.55% to $0.69. On the same session, the stock had its day’s lowest price of $0.60, but rose to a high of $0.6873. Over the last five days, the stock has lost -4.68%. BioCardia Inc. shares have fallen nearly -67.16% since the year began. Dec 15, 2022 · The gross proceeds to BioCardia, before deducting fees and other offering expenses, are expected to be approximately $3.6 million. The closing of the sale of the securities is expected to occur on ...

Convert BioCardia Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. Select a stock. apple; wise; Select a currency. USD. NASDAQ: BioCardia Inc (BCDAW) = 0.06 USD. Provided by Alpha Vantage. BioCardia Inc stock (BCDAW) in USD. 1 BCDAW = 0.06 USD. 1 month.BioCardia stock rises on FDA nod to start trial of stem cell therapy for heart failure Dec. 06, 2022 8:33 AM ET BioCardia, Inc. (BCDA) By: Ravikash , SA News Editor 1 Comment Sarah Silbiger6 hari yang lalu ... BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected ...BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a definitive ...BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules GlobeNewswire 17d Why Beyond Air Shares Are Trading Lower By Around 37%?

BioCardia, Inc. reports earnings inline with expectations. Reported EPS is $-0.12 EPS, expectations were $-0.12. Operator: Ladies and gentlemen, thank you for standing by and welcome to the ...

Stock control is important because it prevents retailers from running out of products, according to the Houston Chronicle. Stock control also helps retailers keep track of goods that may have been lost or stolen.

BioCardia, Inc. (NASDAQ:BCDA) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.05. The business had revenue of $0.82 million for the quarter, compared to analysts' expectations of $0.04 million.Stock Performance. Shares of BioCardia were trading at $0.405 as of November 06. Over the last 52-week period, shares are down 78.11%. Given that these returns are generally negative, long-term ...Ladies and gentlemen, thank you for standing by, and welcome to the BioCardia 2023 third-quarter conference call. (Operator Instructions) Participants of this call are advised that the audio of this conference call is being broadcasted live over the Internet and is also being recorded for playback purposes. A webcast replay of this call will be ...Stock Price Forecast. The 1 analysts offering 12-month price forecasts for BioCardia Inc have a median target of 4.00, with a high estimate of 4.00 and a low estimate of 4.00. The median estimate ...November 15, 2023 at 8:04 AM · 3 min read. Shares of BioCardia BCDA skyrocketed 168.2% on Tuesday after management announced that the FDA approved its proposed late-stage CardiAMP Heart Failure ...

Over the past 3 months, 4 analysts have published their opinion on BioCardia (NASDAQ:BCDA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a ...2023. 2023 BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. 14 Nov. 2023 BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure. 2023 BioCardia Reports Third Quarter 2023 Business Highlights and …Stock screener. Filter, compare, and track stocks. Insiders trading. See how executives trade. Heat map. Visualize ratios & metrics. Histogram. See ratios across industries. ... As the Vice President - Operations of BioCardia, the total compensation of Phil Pesta at BioCardia is $276,000.SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular ...Stock Price Forecast. According to 1 stock analyst, the 12-month stock price forecast for BioCardia stock is $4.00, which predicts an increase of 543.92%. On average, analysts rate BioCardia stock as a strong buy.Get the latest BioCardia Inc (BCDA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

Find the latest BioCardia, Inc. (BCDAW) stock quote, history, news and other vital information to help you with your stock trading and investing.Nov 29, 2023 · The BioCardia, Inc. stock price fell by -0.92% on the last day (Wednesday, 29th Nov 2023) from $0.686 to $0.680. It has now fallen 3 days in a row. During the last trading day the stock fluctuated 11.30% from a day low at $0.639 to a day high of $0.711. The price has fallen in 8 of the last 10 days and is down by -36.45% for this period.

BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq ...Nov 14, 2023 · SUNNYVALE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ... Find real-time BCDA - BioCardia Inc stock quotes, company profile, news and forecasts from CNN Business. Mohammed Haneefa Nizamudeen. I first wrote about BioCardia (NASDAQ:BCDA) in June of 2021, explaining why I'd taken a speculative-sized position in the stock.Since then the share price is down (as ...NRBO. Neurobo Pharmaceuticals Inc. 0.442. -0.006. -1.3393%. Get BioCardia Inc (BCDA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Biocardia trades on the NASDAQ stock market under the symbol BCDA. What is Biocardia stock price doing today? As of November 29, 2023, BCDA stock price declined to $0.68 with 702,007 million shares trading.

BCDA Stock Shows Promising Performance with Potential 863.86% Increase: Analysts Recommend Buying BioCardia Inc. BCDA stock has shown promising performance on November 7, 2023, according to data sourced from CNN Money. The median target price is $4.00, indicating a potential increase of 863.86% from the last recorded price of $0.42.

2023 BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. 14 Nov 2023 BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure. 08 Nov

Peter Altman became the CEO of BioCardia, Inc. (NASDAQ:BCDA) in 2002, and we think it's a good time to look at the...Sep 5, 2023 · SUNNYVALE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- BioCardia ®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ... Stock analysis for BioCardia Inc (BCDA:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.5 Sep 2023 ... Biocardia stock dropped from about $2 on July 21 to $1.10 on July 24, when the concerns of the DSMB were first revealed. After drifting down ...The estimated Net Worth of Richard M Krasno is at least $385 Thousand dollars as of 17 June 2019. Mr. Krasno owns over 20,000 units of BioCardia stock worth over $114,800 and over the last 17 years he sold BCDA stock worth over $0. In addition, he makes $269,814 as Independent Director at BioCardia.With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.BioCardia Stock Up 8.2 %. NASDAQ BCDA opened at $0.67 on Friday. The firm’s fifty day moving average price is $0.50 and its two-hundred day moving average price is $1.17. BioCardia has a 1 year ...Find the latest BioCardia, Inc. (6JU.F) stock quote, history, news and other vital information to help you with your stock trading and investing.

About BioCardia. BioCardia, Inc., headquartered in Sunnyvale, California, is a developer of two biotherapeutic platforms – the CardiAMP autologous bone marrow derived mononuclear cell therapy for cardiovascular indications, and the NK1R+ allogeneic bone marrow derived mesenchymal stem cell therapies for cardiovascular and pulmonary diseases.BioCardia Inc (NASDAQ: BCDA) said the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the ongoing Phase 3 pivotal CardiAMP Cell BioCardia stock has received a consensus rating of buy. The average rating score is and is based on 9 buy ratings, 0 hold ratings, and 0 sell ratings. What was the 52-week low for BioCardia stock? Instagram:https://instagram. telemedicine stockswarren buffet squishmallowwall street journal customer centerhow to start cryptocurrency trading Allan Tessler BCDA stock SEC Form 4 insiders trading. Allan has made over 11 trades of the BioCardia stock since 2006, according to the Form 4 filled with the SEC. Most recently Allan bought 400 units of BCDA stock worth $199,200 on 9 March 2020.400 units of BCDA stock worth $199,200 on 9 March 2020.BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq ... j.m.smuckermost sustainable companies Over the last 7 years, insiders at BioCardia have traded over $2,500,000 worth of BioCardia stock and bought 6,474,371 units worth $6,325,055 . The most active insiders traders include Phillip Md Et Al Frost Gamm..., Simon H Stertzer, and Richard M Krasno. On average, BioCardia executives and independent directors trade stock every …BCDA Stock Shows Promising Performance with Potential 863.86% Increase: Analysts Recommend Buying BioCardia Inc. BCDA stock has shown promising performance on November 7, 2023, according to data sourced from CNN Money. The median target price is $4.00, indicating a potential increase of 863.86% from the last recorded price of $0.42. nyse insp Over the last 7 years, insiders at BioCardia have traded over $2,500,000 worth of BioCardia stock and bought 6,474,371 units worth $6,325,055 . The most active insiders traders include Phillip Md Et Al Frost Gamm..., Simon H Stertzer, and Richard M Krasno. On average, BioCardia executives and independent directors trade stock every …BioCardia beats Genocea Biosciences on 6 of the 11 factors compared between the two stocks. About BioCardia (Get Free Report) BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is …Get the latest BioCardia, Inc. (BCDA) stock news and headlines to help you in your trading and investing decisions. ... 2023 BioCardia, Inc. reports earnings inline with expectations. Reported EPS ...